Xin Wang, You Li, Ting Shi, Yiming Ma, Bhanu Wahi-Singh, Richard D Riley, Harish Nair
Existing guidelines on respiratory syncytial virus (RSV) prophylaxis differ greatly by gestational age (GA) and other underlying risk factors, highlighting the data gaps in RSV disease burden among preterm infants. We will conduct a systematic review and individual participant data (IPD) meta-analysis of RSV global disease burden among preterm-born children. Three databases, Medline, Embase, and Global Health, will be searched for relevant studies on RSV disease burden for 2019 or before in preterm-born children published between 1 January 1995 and 31 December 2021. IPD will be sought by contacting the investigators identified from published literature and from existing collaboration networks. One-stage and 2-stage random-effects meta-analyses will be used to combine information from IPD and non-IPD studies to produce summary RSV burden estimates of incidence rate, hospital admission rate, and in-hospital case fatality ratio. The framework will be extended to examine subgroup(s) with the most substantial RSV disease burden.
{"title":"Global Disease Burden of Respiratory Syncytial Virus in Preterm Children in 2019: A Systematic Review and Individual Participant Data Meta-Analysis Protocol.","authors":"Xin Wang, You Li, Ting Shi, Yiming Ma, Bhanu Wahi-Singh, Richard D Riley, Harish Nair","doi":"10.1093/infdis/jiac078","DOIUrl":"10.1093/infdis/jiac078","url":null,"abstract":"<p><p>Existing guidelines on respiratory syncytial virus (RSV) prophylaxis differ greatly by gestational age (GA) and other underlying risk factors, highlighting the data gaps in RSV disease burden among preterm infants. We will conduct a systematic review and individual participant data (IPD) meta-analysis of RSV global disease burden among preterm-born children. Three databases, Medline, Embase, and Global Health, will be searched for relevant studies on RSV disease burden for 2019 or before in preterm-born children published between 1 January 1995 and 31 December 2021. IPD will be sought by contacting the investigators identified from published literature and from existing collaboration networks. One-stage and 2-stage random-effects meta-analyses will be used to combine information from IPD and non-IPD studies to produce summary RSV burden estimates of incidence rate, hospital admission rate, and in-hospital case fatality ratio. The framework will be extended to examine subgroup(s) with the most substantial RSV disease burden.</p>","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"5 1","pages":"S135-S141"},"PeriodicalIF":0.0,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72788629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pablo Guisado-Vasco, José Aguarles Gorines, María M Carralón González, Gabriel Sotres Fernández, Daniel Carnevali Ruiz
Use of interleukin (IL-6) inhibitors has become one of the most complicated clinical issues in treating coronavirus disease 2019 (COVID-19). Recently, randomized open-label platform trials have found that IL-6 inhibitors have a beneficial effect on mortality in severe COVID-19. However, several questions arise around their mechanism of action in this disease, as well as how, when, and at which dose they should be used. IL-6 has both proinflammatory and anti-inflammatory effects, which may modulate the course of COVID-19, whose immunopathogenesis is driven by the innate immune system, autoantibodies, and interferon. Given that patients with delayed seroconversion against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein would be at the highest risk of complications beyond the second week of disease, we propose that considering patient serostatus at admission could optimize the use of IL-6 inhibitors in COVID-19. We predict that the net treatment benefits could be higher in the subgroup of patients with delayed seroconversion as compared to those who seroconvert more rapidly after SARS-CoV-2 infection.
{"title":"Flipped Inflammatory Time and the Role of Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2: Optimizing Tocilizumab Against Coronavirus Disease 2019.","authors":"Pablo Guisado-Vasco, José Aguarles Gorines, María M Carralón González, Gabriel Sotres Fernández, Daniel Carnevali Ruiz","doi":"10.1093/infdis/jiac090","DOIUrl":"10.1093/infdis/jiac090","url":null,"abstract":"<p><p>Use of interleukin (IL-6) inhibitors has become one of the most complicated clinical issues in treating coronavirus disease 2019 (COVID-19). Recently, randomized open-label platform trials have found that IL-6 inhibitors have a beneficial effect on mortality in severe COVID-19. However, several questions arise around their mechanism of action in this disease, as well as how, when, and at which dose they should be used. IL-6 has both proinflammatory and anti-inflammatory effects, which may modulate the course of COVID-19, whose immunopathogenesis is driven by the innate immune system, autoantibodies, and interferon. Given that patients with delayed seroconversion against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein would be at the highest risk of complications beyond the second week of disease, we propose that considering patient serostatus at admission could optimize the use of IL-6 inhibitors in COVID-19. We predict that the net treatment benefits could be higher in the subgroup of patients with delayed seroconversion as compared to those who seroconvert more rapidly after SARS-CoV-2 infection.</p>","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"254 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75936811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Latar belakang: Tuberkulosis (TB) adalah penyakit infeksi menular yang disebabkan oleh Mycobacterium tuberculosis (MTB) dan salah satu dari 10 penyebab kematian di dunia, 11% kasus diantaranya adalah anak-anak. Tujuan Penelitian: Penelitian ini bertujuan untuk mengetahui karakteristik, manifestasi klinis, gambaran riwayat kesehatan pasien, pengobatan, dan efek samping obat tuberculosis anak. Metode: Penelitian deskriptif. Data bersumber dari rekam medik dan form TB 01 periode Januari-Desember 2018. Hasil: Mayoritas pasien adalah anak laki-laki berusia 1-4 tahun. Manifestasi klinis batuk ditemukan sebanyak 71,8%; demam 53,8%; pembesaran KGB 43,6%; dan penurunan berat badan 33,3%. Sebagian besar (84,6%) tidak ada riwayat kontak dengan penderita TB dan 30.8% sudah mendapatkan imunisasi BCG. Sebanyak 46.2% memiliki hasil uji tuberculin positif dan hasil foto gambaran khas TB pada foto thorax. Berdasarkan riwayat kesehatan, 46.2% di antaranya bergizi baik, 89.7% merupakan pasien baru dan hanya 15 anak dengan penyakit penyerta. Pada studi ini, sebagian besar (82,1%) mendapatkan Obat Anti Tuberkulosis (OAT) anak, dengan kombinasi obat HRZ pada tahap intensif 61,5% dengan lama pengobatan 6 bulan sebanyak 48,7%. Kesimpulan: Terdapat variasi spektrum klinis yang luas pada TB anak dengan pengobatan OAT.
{"title":"Profil Tuberkulosis Paru Pada Anak di RSPI Prof. Dr. Sulianti Saroso","authors":"Agatha Nagrintya Ginting, Kriston Silitonga, Suliati Suliati, Farida Murtiani","doi":"10.32667/ijid.v8i1.134","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.134","url":null,"abstract":"Latar belakang: Tuberkulosis (TB) adalah penyakit infeksi menular yang disebabkan oleh Mycobacterium tuberculosis (MTB) dan salah satu dari 10 penyebab kematian di dunia, 11% kasus diantaranya adalah anak-anak. Tujuan Penelitian: Penelitian ini bertujuan untuk mengetahui karakteristik, manifestasi klinis, gambaran riwayat kesehatan pasien, pengobatan, dan efek samping obat tuberculosis anak. Metode: Penelitian deskriptif. Data bersumber dari rekam medik dan form TB 01 periode Januari-Desember 2018. Hasil: Mayoritas pasien adalah anak laki-laki berusia 1-4 tahun. Manifestasi klinis batuk ditemukan sebanyak 71,8%; demam 53,8%; pembesaran KGB 43,6%; dan penurunan berat badan 33,3%. Sebagian besar (84,6%) tidak ada riwayat kontak dengan penderita TB dan 30.8% sudah mendapatkan imunisasi BCG. Sebanyak 46.2% memiliki hasil uji tuberculin positif dan hasil foto gambaran khas TB pada foto thorax. Berdasarkan riwayat kesehatan, 46.2% di antaranya bergizi baik, 89.7% merupakan pasien baru dan hanya 15 anak dengan penyakit penyerta. Pada studi ini, sebagian besar (82,1%) mendapatkan Obat Anti Tuberkulosis (OAT) anak, dengan kombinasi obat HRZ pada tahap intensif 61,5% dengan lama pengobatan 6 bulan sebanyak 48,7%. Kesimpulan: Terdapat variasi spektrum klinis yang luas pada TB anak dengan pengobatan OAT.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81612116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Latar belakang: Vitamin D merupakan salah satu vitamin yang dapat melalui penghambatan respons sel T helper tipe 1 dan merangsang induksi sel T. Hal ini menunjukkan efek perlindungan vitamin D terhadap status infeksi virus pernapasan pada pasien COVID-19. Tujuan: mengetahui hubungan antara kadar Vitamin D dengan derajat penyakit COVID-19. Metode: rancangan penelitian deskriptif korelasional dengan metode analitik melalui pendekatan cross sectional. Total sampel 547 sampel pasien COVID-19 RSPI Sulianti Saroso periode Maret-Desember Tahun 2020. Hasil: Jumlah pasien rawat inap tahun 2020 sebanyak 547 pasien COVID-19, rata-rata usia 47,74 tahun, jenis kelamin laki-laki (55%), dengan komorbid (penyakit penyerta) (58,7%), rata-rata vitamin D 17.94 ng/ml dalam kategori defisiensi < 20 ng/ml (64,2%), derajat keparahan sedang (81,9%). Hasil uji chi square diperoleh nilai p value 0,518 (> 0,05) dengan menggunakan alpha 5% (0,05) berarti tidak ada hubungan antara Vitamin D dengan derajat keparahan pada pasien COVID-19 Kesimpulan: Kadar Vitamin D tidak berhubungan dengan derajat keparahan COVID-19
{"title":"Hubungan Antara Kadar Vitamin D dengan Derajat Keparahan COVID-19","authors":"Handoko Handoko, Angki Purwanti, Dian Wahyu Tanjungsari, I. Pertiwi, Farida Murtiani","doi":"10.32667/ijid.v8i1.130","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.130","url":null,"abstract":"Latar belakang: Vitamin D merupakan salah satu vitamin yang dapat melalui penghambatan respons sel T helper tipe 1 dan merangsang induksi sel T. Hal ini menunjukkan efek perlindungan vitamin D terhadap status infeksi virus pernapasan pada pasien COVID-19. Tujuan: mengetahui hubungan antara kadar Vitamin D dengan derajat penyakit COVID-19. Metode: rancangan penelitian deskriptif korelasional dengan metode analitik melalui pendekatan cross sectional. Total sampel 547 sampel pasien COVID-19 RSPI Sulianti Saroso periode Maret-Desember Tahun 2020. Hasil: Jumlah pasien rawat inap tahun 2020 sebanyak 547 pasien COVID-19, rata-rata usia 47,74 tahun, jenis kelamin laki-laki (55%), dengan komorbid (penyakit penyerta) (58,7%), rata-rata vitamin D 17.94 ng/ml dalam kategori defisiensi < 20 ng/ml (64,2%), derajat keparahan sedang (81,9%). Hasil uji chi square diperoleh nilai p value 0,518 (> 0,05) dengan menggunakan alpha 5% (0,05) berarti tidak ada hubungan antara Vitamin D dengan derajat keparahan pada pasien COVID-19 Kesimpulan: Kadar Vitamin D tidak berhubungan dengan derajat keparahan COVID-19","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81159628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Herlina, Anita Puspitasari Dyah Nugroho, Siti Maemun, Intansari Pertiwi, Andi Dala Intan Sapta Nanda, Farida Murtiani
Latar Belakang:. Penyakit Coronavirus 2019 merupakan penyakit sistem pernapasan yang baru saja muncul dan menjadi pandemi. Indonesia mengalami peningkatan jumlah kasus yang cukup drastis. Derajat keparahan yang dialami oleh pasien COVID-19 dapat dipengaruhi oleh berbagai hal seperti usia, penyakit komorbid, defisiensi vitamin D, dan obesitas. Penelitian ini bertujuan untuk mengetahui hubungan jumlah komorbid dan derajat keparahan terhadap kematian pada pasien COVID-19. Metode: Penelitian deskriptif analitik dengan rancangan cross sectional. Total sampel 1240 pasien COVID-19 RSPI Sulianti Saroso Tahun 2020 2021. Hasil: Komorbid terbanyak adalah hipertensi dan diabetes melitus, derajat keparahan kategori sedang dan outcome hidup. Hasil analisis ada hubungan antara jumlah komorbid dengan status kematian (OR=1,585). Ada hubungan diabetes melitus dengan status kematian pasien pada pasien COVID-19 (OR=1,927). Ada hubungan antara derajat keparahan dengan status kematian pada pasien COVID-19 (OR=12,699). Kesimpulan: Derajat keparahan, jumlah komorbid dan komorbid diabetes mellitus berhubungan merupakan faktor risiko kematian pada pasien COVID-19.
{"title":"Kematian pada Pasien COVID-19 Berdasarkan Komorbid dan Tingkat Keparahan","authors":"H. Herlina, Anita Puspitasari Dyah Nugroho, Siti Maemun, Intansari Pertiwi, Andi Dala Intan Sapta Nanda, Farida Murtiani","doi":"10.32667/ijid.v8i1.135","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.135","url":null,"abstract":"Latar Belakang:. Penyakit Coronavirus 2019 merupakan penyakit sistem pernapasan yang baru saja muncul dan menjadi pandemi. Indonesia mengalami peningkatan jumlah kasus yang cukup drastis. Derajat keparahan yang dialami oleh pasien COVID-19 dapat dipengaruhi oleh berbagai hal seperti usia, penyakit komorbid, defisiensi vitamin D, dan obesitas. Penelitian ini bertujuan untuk mengetahui hubungan jumlah komorbid dan derajat keparahan terhadap kematian pada pasien COVID-19. Metode: Penelitian deskriptif analitik dengan rancangan cross sectional. Total sampel 1240 pasien COVID-19 RSPI Sulianti Saroso Tahun 2020 2021. Hasil: Komorbid terbanyak adalah hipertensi dan diabetes melitus, derajat keparahan kategori sedang dan outcome hidup. Hasil analisis ada hubungan antara jumlah komorbid dengan status kematian (OR=1,585). Ada hubungan diabetes melitus dengan status kematian pasien pada pasien COVID-19 (OR=1,927). Ada hubungan antara derajat keparahan dengan status kematian pada pasien COVID-19 (OR=12,699). Kesimpulan: Derajat keparahan, jumlah komorbid dan komorbid diabetes mellitus berhubungan merupakan faktor risiko kematian pada pasien COVID-19.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87532605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Kurniasih, Fitrian Rayasari, Ahmad Zubairi, S. Suryati, Kunti Wijiarti, Farida Murtiani
Latar Belakang: Penurunan saturasi pada pasien COVID-19 dengan pneumonia dapat dicegah dengan program pemberian posisi salah satunya posisi pronasi. Penelitian ini bertujuan mengetahui pengaruh posisi pronasi terhadap peningkatan saturasi oksigen pada pasien COVID-19 dengan pneumonia. Metode: Quasi eksperimen pretest tanpa kelompok kontrol. Penelitian dilakukan di 2 RS yaitu RSPI Prof Dr Sulianti Saroso dan RSUD Tarakan pada tanggal 8 Maret- 29 April 2021. Jumlah responden sebanyak 24 orang (RSPI SSS: 8 responden dan RS Tarakan: 16 responden). Hasil: Rata-rata pasien adalah laki-laki (19 orang) berusia 55,54 tahun, tidak ada riwayat DM (14 orang) dan memiliki riwayat hipertensi (17 orang). Sebelum intervensi rata-rata SpO2 96.53% dan RR 25.60 x/menit. Sesudah Intervensi rata – rata SpO2 97.36% dan RR 24.59 x/menit. Ada peningkatan nilai SpO2 sebesar 0.83% (Pvalue=0,000), dan ada penurunan RR 1.01 x/menit (Pvalue-0,000). Kesimpulan: ada pengaruh dari penerapan posisi pronasi terhadap peningkatan oksigenasi pada pasien COVID-19 dengan pneumonia.
{"title":"Penerapan Posisi Pronasi Terhadap Peningkatan Oksigenasi Pada Pasien COVID-19 Dengan Pneumonia","authors":"D. Kurniasih, Fitrian Rayasari, Ahmad Zubairi, S. Suryati, Kunti Wijiarti, Farida Murtiani","doi":"10.32667/ijid.v8i1.133","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.133","url":null,"abstract":"Latar Belakang: Penurunan saturasi pada pasien COVID-19 dengan pneumonia dapat dicegah dengan program pemberian posisi salah satunya posisi pronasi. Penelitian ini bertujuan mengetahui pengaruh posisi pronasi terhadap peningkatan saturasi oksigen pada pasien COVID-19 dengan pneumonia. Metode: Quasi eksperimen pretest tanpa kelompok kontrol. Penelitian dilakukan di 2 RS yaitu RSPI Prof Dr Sulianti Saroso dan RSUD Tarakan pada tanggal 8 Maret- 29 April 2021. Jumlah responden sebanyak 24 orang (RSPI SSS: 8 responden dan RS Tarakan: 16 responden). Hasil: Rata-rata pasien adalah laki-laki (19 orang) berusia 55,54 tahun, tidak ada riwayat DM (14 orang) dan memiliki riwayat hipertensi (17 orang). Sebelum intervensi rata-rata SpO2 96.53% dan RR 25.60 x/menit. Sesudah Intervensi rata – rata SpO2 97.36% dan RR 24.59 x/menit. Ada peningkatan nilai SpO2 sebesar 0.83% (Pvalue=0,000), dan ada penurunan RR 1.01 x/menit (Pvalue-0,000). Kesimpulan: ada pengaruh dari penerapan posisi pronasi terhadap peningkatan oksigenasi pada pasien COVID-19 dengan pneumonia.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"16 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78169743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Latar belakang: COVID-19 menjadi masalah kesehatan di dunia. Penanda inflamasi yang dapat digunakan sebagai predictor prognosis COVID-19 salah satunya Interlukin-6 (IL-6) dan Neutrofil Lymphocyte Ratio (NLR). Tujuan penelitian: mengetahui hubungan kadar IL-6 dengan NLR pada pasien COVID-19. Metode: Penelitian kuantitatif dengan desain cross sectional. Data yang dikumpulkan dari rekam medik pasien COVID-19 di RS Kanker Dharmais periode Januari-Juli 2021. Jumlah sampel sebanyak 70 pasien yang memenuhi kriteria inklusi dan eksklusi. Analisa data dilakukan secara univariat dan bivariat dengan korelasi spearman. Hasil: Dari 70 pasien COVID-19 sebagian besar berusia dalam kategori lansia akhir (56-65 Tahun) 17 (24,3%) dan jenis kelamin sebagian besar laki-laki yaitu 42 (60%). Rata-rata kadar IL-6 43,34 pg/ml dan rata-rata NLR 12,73. Ada korelasi antara kadar IL-6 dengan NLR pada pasien COVID-19 (P Value=0,000; nilai r 0.563). Kesimpulan: Adanya korelasi positif IL-6 dengan NLR. IL-6 adalah salah satu biomarker yang digunakan untuk memprediksi prognosis COVID-19 karena pemeriksaannya yg kompleks, tidak dapat memprosesnya di lab yg sederhana. Sebagai gantinya, kami menyimpulkan pemeriksaan NLR dapat menjadi biomarker alternatif.
背景:COVID-19已经成为世界卫生问题。炎症标记可作为预习预后的COVID-19和神经丝素ramphocyte Ratio (NLR)。研究目的:确定科维-19患者的ir -6与NLR的联系。方法:交叉设计的定量研究。数据来自于2021年1月至7月期间达摩癌症医院COVID-19患者的医疗记录。共有70名符合纳入和排斥标准的患者样本。数据分析是与spearman相关的univariat和bivariat进行的。结果:70名患者中，大多数是晚期老年人(56-65岁)17(243%)，大多数男性是42(60%)。平均g -6 - 43.34 pg/ml, NLR平均12.73。在患者COVID-19中，il6级与NLR之间存在关联。0.563值。结论:y -6与NLR之间有正相关。il6是用来预测COVID-19预后的生物标记之一，因为它的复写形式非常复杂，无法在简单的实验室中处理。相反，我们的结论是，NLR检查可能是另一种生物标记。
{"title":"Hubungan Kadar Interleukin-6 (IL-6) Dengan Neutrophil Lymphocyte Ratio (NLR) Pada Pasien COVID- 19","authors":"Sriyanto Sriyato, Lyana Setiawan, Rizana Fajrunni’mah, Farida Murtiani","doi":"10.32667/ijid.v8i1.132","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.132","url":null,"abstract":"Latar belakang: COVID-19 menjadi masalah kesehatan di dunia. Penanda inflamasi yang dapat digunakan sebagai predictor prognosis COVID-19 salah satunya Interlukin-6 (IL-6) dan Neutrofil Lymphocyte Ratio (NLR). Tujuan penelitian: mengetahui hubungan kadar IL-6 dengan NLR pada pasien COVID-19. Metode: Penelitian kuantitatif dengan desain cross sectional. Data yang dikumpulkan dari rekam medik pasien COVID-19 di RS Kanker Dharmais periode Januari-Juli 2021. Jumlah sampel sebanyak 70 pasien yang memenuhi kriteria inklusi dan eksklusi. Analisa data dilakukan secara univariat dan bivariat dengan korelasi spearman. Hasil: Dari 70 pasien COVID-19 sebagian besar berusia dalam kategori lansia akhir (56-65 Tahun) 17 (24,3%) dan jenis kelamin sebagian besar laki-laki yaitu 42 (60%). Rata-rata kadar IL-6 43,34 pg/ml dan rata-rata NLR 12,73. Ada korelasi antara kadar IL-6 dengan NLR pada pasien COVID-19 (P Value=0,000; nilai r 0.563). Kesimpulan: Adanya korelasi positif IL-6 dengan NLR. IL-6 adalah salah satu biomarker yang digunakan untuk memprediksi prognosis COVID-19 karena pemeriksaannya yg kompleks, tidak dapat memprosesnya di lab yg sederhana. Sebagai gantinya, kami menyimpulkan pemeriksaan NLR dapat menjadi biomarker alternatif. ","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75892757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-18DOI: 10.1101/2022.07.18.22277741
B. Cowling, S. Cheng, M. Martín-Sánchez, N. Y. M. Au, K. Chan, John K. C. Li, Lison W C Fung, L. Luk, L. Tsang, D. Ip, Leo L. M. Poon, G. Leung, J. Peiris, N. Leung
Introduction: Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the risk of symptomatic infection and the risk of severe disease. Third doses have been particularly important for improving protection against variants. However, waning of clinical protection particularly against Omicron has been noted after receipt of third doses. Methods: We administered BNT162b2 as a third dose to adults aged [≥]30 years who had previously received two doses of inactivated vaccination. We collected blood before the third dose and again after one month and six months, and tested sera using a spike receptor binding domain IgG enzyme-linked immunosorbent assay, a surrogate virus neutralization test, and live virus plaque reduction neutralization assay against ancestral virus and Omicron BA.2. Results: We administered BNT162b2 as a third dose to 314 adults. We found robust antibody responses to the ancestral strain at six months after receipt of BNT162b2. Antibody responses to Omicron BA.2 were weaker after the third dose and had declined to a low level by six months. From a small number of participants we observed that natural infection or a fourth dose of vaccination generated similar antibody levels against ancestral virus, but infection generated higher antibody level against Omicron BA.2 than vaccination, suggesting a potential advantage in the breadth of antibody response from hybrid immunity. Conclusions: While antibody levels against the ancestral strain remained robust at six months after the third dose, antibody levels against Omicron BA.2 had fallen to low levels suggesting the potential benefits of a fourth dose.
{"title":"Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine","authors":"B. Cowling, S. Cheng, M. Martín-Sánchez, N. Y. M. Au, K. Chan, John K. C. Li, Lison W C Fung, L. Luk, L. Tsang, D. Ip, Leo L. M. Poon, G. Leung, J. Peiris, N. Leung","doi":"10.1101/2022.07.18.22277741","DOIUrl":"https://doi.org/10.1101/2022.07.18.22277741","url":null,"abstract":"Introduction: Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the risk of symptomatic infection and the risk of severe disease. Third doses have been particularly important for improving protection against variants. However, waning of clinical protection particularly against Omicron has been noted after receipt of third doses. Methods: We administered BNT162b2 as a third dose to adults aged [≥]30 years who had previously received two doses of inactivated vaccination. We collected blood before the third dose and again after one month and six months, and tested sera using a spike receptor binding domain IgG enzyme-linked immunosorbent assay, a surrogate virus neutralization test, and live virus plaque reduction neutralization assay against ancestral virus and Omicron BA.2. Results: We administered BNT162b2 as a third dose to 314 adults. We found robust antibody responses to the ancestral strain at six months after receipt of BNT162b2. Antibody responses to Omicron BA.2 were weaker after the third dose and had declined to a low level by six months. From a small number of participants we observed that natural infection or a fourth dose of vaccination generated similar antibody levels against ancestral virus, but infection generated higher antibody level against Omicron BA.2 than vaccination, suggesting a potential advantage in the breadth of antibody response from hybrid immunity. Conclusions: While antibody levels against the ancestral strain remained robust at six months after the third dose, antibody levels against Omicron BA.2 had fallen to low levels suggesting the potential benefits of a fourth dose.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73918906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Gómez-Carballa, S. Pischedda, I. Rivero-Calle, J. Montoto-Louzao, F. Martinon-Torres, A. Salas
{"title":"CD14 and related genes in respiratory morbidity after Respiratory Syncytial Virus infection.","authors":"A. Gómez-Carballa, S. Pischedda, I. Rivero-Calle, J. Montoto-Louzao, F. Martinon-Torres, A. Salas","doi":"10.1093/infdis/jiac248","DOIUrl":"https://doi.org/10.1093/infdis/jiac248","url":null,"abstract":"","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90410210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-16DOI: 10.1101/2022.06.15.22276439
T. van der Maaden, Elizabeth N Mutubuki, S. de Bruijn, K. Y. Leung, H. Knoop, Jaap Slootweg, A. D. Tulen, A. Wong, A. V. van Hoek, E. Franz, C. C. van den Wijngaard
Background: More information is needed on prevalence of long-term symptoms after SARS-CoV-2-infection. This prospective study assesses symptoms three months after SARS-CoV-2-infection compared to test-negative and population controls, and the effect of vaccination prior to infection. Methods: Participants enrolled after a positive (cases) or negative (test-negative controls) SARS-CoV-2-test, or after invitation from the general population (population controls). After three months, participants indicated presence of 41 symptoms, and severity of four symptoms. Permutation tests were used to select symptoms significantly elevated in cases compared to controls and to compare symptoms between cases that were vaccinated or unvaccinated prior to infection. Findings: Between May 19th and December 13th 2021 9166 cases, 1698 symptomatic but test-negative controls, and 3708 population controls enrolled. At three months, 13 symptoms, and severity of fatigue, cognitive impairment and dyspnoea, were significantly elevated between cases and controls. Of cases, 48.5% reported [≥]1 significantly elevated symptom, compared to 29.8% of test-negative controls and 26.0% of population controls. Effect of vaccination could only be determined for cases <65yrs, and was found to be significantly protective for loss of smell and taste but not for other symptoms. Interpretation: Three months after SARS-CoV-2 infection, almost half of the cases still report symptoms, which is higher than the background prevalence and prevalence in test-negative controls. Vaccination prior to infection was protective against loss of smell and taste as assessed in cases aged <65.
{"title":"Prevalence and severity of symptoms 3 months after infection with SARS-CoV-2 compared to test-negative and population controls in the Netherlands","authors":"T. van der Maaden, Elizabeth N Mutubuki, S. de Bruijn, K. Y. Leung, H. Knoop, Jaap Slootweg, A. D. Tulen, A. Wong, A. V. van Hoek, E. Franz, C. C. van den Wijngaard","doi":"10.1101/2022.06.15.22276439","DOIUrl":"https://doi.org/10.1101/2022.06.15.22276439","url":null,"abstract":"Background: More information is needed on prevalence of long-term symptoms after SARS-CoV-2-infection. This prospective study assesses symptoms three months after SARS-CoV-2-infection compared to test-negative and population controls, and the effect of vaccination prior to infection. Methods: Participants enrolled after a positive (cases) or negative (test-negative controls) SARS-CoV-2-test, or after invitation from the general population (population controls). After three months, participants indicated presence of 41 symptoms, and severity of four symptoms. Permutation tests were used to select symptoms significantly elevated in cases compared to controls and to compare symptoms between cases that were vaccinated or unvaccinated prior to infection. Findings: Between May 19th and December 13th 2021 9166 cases, 1698 symptomatic but test-negative controls, and 3708 population controls enrolled. At three months, 13 symptoms, and severity of fatigue, cognitive impairment and dyspnoea, were significantly elevated between cases and controls. Of cases, 48.5% reported [≥]1 significantly elevated symptom, compared to 29.8% of test-negative controls and 26.0% of population controls. Effect of vaccination could only be determined for cases <65yrs, and was found to be significantly protective for loss of smell and taste but not for other symptoms. Interpretation: Three months after SARS-CoV-2 infection, almost half of the cases still report symptoms, which is higher than the background prevalence and prevalence in test-negative controls. Vaccination prior to infection was protective against loss of smell and taste as assessed in cases aged <65.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91326539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号